SCHEMBL512955

SCHEMBL512955

Cc1cccc(-c2nnn(C[Si](C)(C)C)n2)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.63
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
KCNJ6 P48051 1/20 0.43
KCNJ5 P48544 1/20 0.43
KCNJ3 P48549 1/20 0.43
RAB9A P51151 7/20 0.43
NPC1 O15118 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
TSHR P16473 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
GRM5 P41594 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377871 0.84 TRPM8 (0.62) LMNAMEN1KMT2ATRPM8KCNJ6
SCHEMBL513787 0.82 RAB9A (0.61) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL513853 0.77 LMNA (0.54) LMNAMEN1KMT2ATRPM8RAB9A
SCHEMBL20114352 0.75 TSHR (0.75) LMNAMEN1KMT2AKCNJ6KCNJ5
SCHEMBL17922234 0.73 LMNA (0.50) LMNAMEN1KMT2ATRPM8RAB9A
SCHEMBL6617494 0.69 LMNA (0.46) LMNAMEN1KMT2ARAB9ANPC1
SCHEMBL13947396 0.68 SMN1; SMN2 (0.54) LMNATRPM8RAB9ANPC1SMN1; SMN2
SCHEMBL3766697 0.67 RAB9A (0.73) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL13947009 0.67 SMN1; SMN2 (0.53) LMNATRPM8RAB9ANPC1SMN1; SMN2
SCHEMBL13892292 0.67 XPO1 (0.58) LMNAMEN1KMT2ATRPM8KCNJ6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477981-A1 HETEROCYCLIC MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2012-07-25 EP disclosed
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 LMNA 1601/4885MEN1 483/4885KMT2A 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.